Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

Capucine Baldini, Stéphane Champiat, Perrine Vuagnat, Christophe Massard Drug Development Department, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France Abstract: Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incid...

Full description

Bibliographic Details
Main Authors: Baldini C, Champiat S, Vuagnat P, Massard C
Format: Article
Language:English
Published: Dove Medical Press 2019-04-01
Series:OncoTargets and Therapy
Subjects:
Immunotherapy
PD-L1 inhibitor
Durvalumab
Urothelial carcinoma
Bladder cancer
Online Access:https://www.dovepress.com/durvalumab-for-the-management-of-urothelial-carcinoma-a-short-review-o-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/durvalumab-for-the-management-of-urothelial-carcinoma-a-short-review-o-peer-reviewed-article-OTT

Similar Items